• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages

tetano

Editor, Senior Moderator
NPJ Vaccines. 2019 May 15;4:17. doi: 10.1038/s41541-019-0111-y. eCollection 2019.
[h=1]Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages.[/h] Makarkov AI[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Golizeh M[SUP]2[/SUP], Ruiz-Lancheros E[SUP]2[/SUP], Gopal AA[SUP]4,[/SUP][SUP]5[/SUP], Costas-Cancelas IN[SUP]6[/SUP], Chierzi S[SUP]7[/SUP], Pillet S[SUP]2,[/SUP][SUP]8[/SUP], Charland N[SUP]8[/SUP], Landry N[SUP]8[/SUP], Rouiller I[SUP]6,[/SUP][SUP]9[/SUP], Wiseman PW[SUP]4,[/SUP][SUP]10[/SUP], Ndao M[SUP]2,[/SUP][SUP]11[/SUP], Ward BJ[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] A growing body of evidence supports the importance of T cell responses to protect against severe influenza, promote viral clearance, and ensure long-term immunity. Plant-derived virus-like particle (VLP) vaccines bearing influenza hemagglutinin (HA) have been shown to elicit strong humoral and CD4[SUP]+[/SUP] T cell responses in both pre-clinical and clinical studies. To better understand the immunogenicity of these vaccines, we tracked the intracellular fate of a model HA (A/California/07/2009 H1N1) in human monocyte-derived macrophages (MDMs) following delivery either as VLPs (H1-VLP) or in soluble form. Compared to exposure to soluble HA, pulsing with VLPs resulted in ~3-fold greater intracellular accumulation of HA at 15 min that was driven by clathrin-mediated and clathrin-independent endocytosis as well as macropinocytosis/phagocytosis. At 45 min, soluble HA had largely disappeared suggesting its handling primarily by high-degradative endosomal pathways. Although the overall fluorescence intensity/cell had declined 25% at 45 min after H1-VLP exposure, the endosomal distribution pattern and degree of aggregation suggested that HA delivered by VLP had entered both high-degradative late and low-degradative static early and/or recycling endosomal pathways. At 45 min in the cells pulsed with VLPs, HA was strongly co-localized with Rab5, Rab7, Rab11, MHC II, and MHC I. High-resolution tandem mass spectrometry identified 115 HA-derived peptides associated with MHC I in the H1-VLP-treated MDMs. These data suggest that HA delivery to antigen-presenting cells on plant-derived VLPs facilitates antigen uptake, endosomal processing, and cross-presentation. These observations may help to explain the broad and cross-reactive immune responses generated by these vaccines.


[h=4]KEYWORDS:[/h] Cellular immunity; Influenza virus; Recombinant vaccine; Vaccines

PMID: 31123605 PMCID: PMC6520342 DOI: 10.1038/s41541-019-0111-y
 
Back
Top Bottom